Trails Edge Capital Partners LP's 9.9% Ownership in vTv Therapeutics Inc.

Trails Edge Capital Partners, LP, along with Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai, collectively known as the Filers, have reported a 9.9% beneficial ownership in vTv Therapeutics Inc. as of August 29, 2025. The ownership includes 340,536 shares of Class A common stock, consisting of 231,000 shares held directly by Trails Edge Biotechnology and 109,536 shares underlying prefunded warrants. The Filers have certified that the securities were not acquired for the purpose of influencing the control of the issuer. The filing is made under Rule 13d-1(c) and includes a joint filing agreement.